Your browser doesn't support javascript.
loading
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations.
Casado-Arroyo, Ruben; Bernardi, Marco; Sabouret, Pierre; Franculli, Giuseppe; Tamargo, Juan; Spadafora, Luigi; Lellouche, Nicolas; Biondi-Zoccai, Giuseppe; Toth, Peter P; Banach, Maciej.
Afiliação
  • Casado-Arroyo R; Department of Cardiology, H.U.B.-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Bernardi M; Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Sabouret P; Heart Institute, ACTION Study Group-CHU Pitié-Salpétrière Paris, Paris, France.
  • Franculli G; Collège National des Cardiologues Français (CNCF), Paris, France.
  • Tamargo J; Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Spadafora L; Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Lellouche N; Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Biondi-Zoccai G; Service de Cardiologie, AP-HP, University Hospital Henri Mondor, Créteil, France.
  • Toth PP; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
  • Banach M; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Expert Opin Investig Drugs ; 33(9): 967-978, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39096248
ABSTRACT

INTRODUCTION:

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Its prevalence has increased due to worldwide populations that are aging in combination with the growing incidence of risk factors associated. Recent advances in our understanding of AF pathophysiology and the identification of nodal players involved in AF-promoting atrial remodeling highlights potential opportunities for new therapeutic approaches. AREAS COVERED This detailed review summarizes recent developments in the field antiarrhythmic drugs in the field AF. EXPERT OPINION The current situation is far than optimal. Despite clear unmet needs in drug development in the field of AF treatment, the current development of new drugs is absent. The need for a molecule with absence of cardiac and non-cardiac toxicity in the short and long term is a limitation in the field. Improvement in the understanding of AF genetics, pathophysiology, molecular alterations, big data and artificial intelligence with the objective to provide a personalized AF treatment will be the cornerstone of AF treatment in the coming years.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Desenvolvimento de Medicamentos / Antiarrítmicos Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Desenvolvimento de Medicamentos / Antiarrítmicos Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article